Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 141 participants.

Also called NCT01089790

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 141 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01089790
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01089790. Non-randomized; triple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
Acronym
REDWOOD403
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Dutogliptin
Intervention (Drug)
Sitagliptin
Lead sponsor
Forest Laboratories (class: industry)
Collaborator
Phenomix (class: industry)

Record details

Record id
cardio:ct-nct01089790
Content hash
2547b6aa174f3d479ed570e2271010cd79a53f69dc508506616999f9d98ecfad